Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 611 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration February 28, 2019 Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... May 8, 2021 FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer October 22, 2021 What can elephants teach us about cancer? August 12, 2023 Load more HOT NEWS PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... Picking out the patterns: How scientists are finding cancer’s signatures in... Using Artificial Intelligence to Classify Lung Cancer Types, Predict Mutations ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June
